CMS proposes sweeping changes to regenerative medicine reimbursement framework
By EsqSocial Corporation 05/08/22
Last month, the Centers for Medicare & Medicaid Services (CMS) released new and significant proposals impacting Medicare coding, coverage, and reimbursement for a class of regenerative medicines known as “skin substitutes,” a category of therapies that includes certain wound care products as well as human cells, tissues, and cellular and tissue-based products (HCT/Ps). CMS’s proposed changes would affect all such skin substitutes that are furnished in the physician office or hospital outpatient...
By: Hogan Lovells